By Fineline Cube 
German pharmaceutical giant Bayer AG (ETR: BAYN) and the US-based Broad Institute Inc. announced a five-year extension of their long-standing research partnership. The collaboration will continue to advance discoveries in human genomics with a focus on cardiovascular diseases.
Research Focus
The renewed partnership will concentrate on identifying novel targets in precision cardiology. By leveraging an established human cardiomyocyte platform, the collaboration aims to rapidly validate findings and accelerate the development of new therapies.
Targeting Dilated Cardiomyopathy (DCM)
A key focus of the collaboration is the development of potential treatments for dilated cardiomyopathy (DCM), a heart disorder characterized by enlarged heart chambers and impaired pumping efficiency. Without intervention, DCM can progress to heart failure and other serious complications.-Fineline Info & Tech